BioNxt Solutions Inc. (FRA:BXT)
0.5400
0.00 (0.00%)
At close: Sep 30, 2025
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 21.66K CAD in the twelve months ending June 30, 2025, down -29.29% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
21.66K CAD
Revenue Growth
-29.29%
P/S Ratio
4,878.77
Revenue / Employee
n/a
Employees
n/a
Market Cap
65.99M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
BioNxt Solutions News
- 1 day ago - BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization - Wallstreet:Online
- 11 days ago - BioNxt Solutions Announces Closing of Shares for Debt Settlement - Wallstreet:Online
- 11 days ago - Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals - Wallstreet:Online
- 15 days ago - BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development - Wallstreet:Online
- 18 days ago - BioNxt Announces Shares for Debt Settlement - Wallstreet:Online
- 25 days ago - BioNxt Solutions Completes Up-Listing to The OTCQB Market - Wallstreet:Online
- 4 weeks ago - Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt - Wallstreet:Online
- 5 weeks ago - Promotional Activity Engagements - Wallstreet:Online